2022_Poroteros-logo.jpg
Proteros biostructures and Orion Pharma agree on a long-term multi-target collaboration including the assembly of a joint novel and unique HTS small-molecule screening library with the full chemistry support of Enamine
September 06, 2023 04:00 ET | Proteros biostructures GmbH
Multi-target research partnership for drug discovery in oncology and painAssembly of novel high-diversity small molecule library Library collection distinguished by novel unique design concepts based...
2022_Poroteros-logo.jpg
Proteros receives minority investment from private equity firm Inflexion
January 09, 2023 04:00 ET | Proteros biostructures GmbH
MARTINSRIED, Germany and MUNICH, Germany, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Proteros biostructures GmbH, a leading German-based, founder-led contract research organization focused on early-stage...
2022_Poroteros-logo.jpg
Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases
October 25, 2022 08:00 ET | Proteros biostructures GmbH
Proteros selected by Adrestia for its cutting-edge structure-based drug discovery engineProteros to support Adrestia in the discovery of first-in-class drugs for intractable genetic diseasesSignals...